Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Assets: 2016-2025

Historic Other Non-Current Assets for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $2.0 million.

  • Tg Therapeutics' Other Non-Current Assets fell 3.26% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 3.26%. This contributed to the annual value of $2.1 million for FY2024, which is 10.18% down from last year.
  • Tg Therapeutics' Other Non-Current Assets amounted to $2.0 million in Q3 2025, which was up 0.89% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Other Non-Current Assets peaked at $2.3 million during Q4 2023, and registered a low of $1.3 million during Q1 2021.
  • Over the past 3 years, Tg Therapeutics' median Other Non-Current Assets value was $2.0 million (recorded in 2025), while the average stood at $1.8 million.
  • As far as peak fluctuations go, Tg Therapeutics' Other Non-Current Assets soared by 81.38% in 2023, and later fell by 10.18% in 2024.
  • Over the past 5 years, Tg Therapeutics' Other Non-Current Assets (Quarterly) stood at $1.3 million in 2021, then increased by 0.71% to $1.3 million in 2022, then spiked by 81.38% to $2.3 million in 2023, then declined by 10.18% to $2.1 million in 2024, then declined by 3.26% to $2.0 million in 2025.
  • Its Other Non-Current Assets stands at $2.0 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.0 million for Q1 2025.